AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Pictured: Office building science collage

Career Advice

The Top 12 Companies Hiring in Biopharma Now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

February 6, 2025

1 min read

Angela Gabriel

Cosmetologist does injections on the lips and on the face of a beautiful woman in a beauty salon. Cosmetology concept.

Earnings

AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.

February 3, 2025

4 min read

Annalee Armstrong

Human hands symbolizing teamwork working on a pie chart with ai symbol in it. Arms point fingers hold pieces diagram chart. Distribute AI stock options on the market.

Earnings

AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.

January 31, 2025

3 min read

Annalee Armstrong

closeup hot glue gun with melted glue dripping out

Deals

AbbVie Teams Up With Neomorph for Molecular Glue Collab Worth up to $1.64B

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

January 23, 2025

1 min read

Annalee Armstrong

Aerial view of Jersey City skyline at sunset

Job Trends

8 Companies Hiring in New Jersey

Looking for a biopharma job in New Jersey? Check out the BioSpace list of eight companies hiring life sciences professionals like you.

January 23, 2025

2 min read

Angela Gabriel

A piggy bank crammed with $100 bills on a background of American cash

Drug pricing

Novo’s Ozempic, Wegovy Targeted in Second Round of IRA Drug Price Negotiations

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare negotiations or not. CMS has until June 1 to send an initial offer for the adjusted prices.

January 17, 2025

3 min read

Tristan Manalac

San Francisco, USA - May 20, 2022: historic Cable Car Powell Hyde Line on turntable at Powell Street terminal at Market Street in downtown San Francisco, California CA, USA.

Pipeline

JPM25 Day 3: AbbVie, Gilead, GSK and Dyne

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.

January 16, 2025

3 min read

Tristan Manalac

Update: AbbVie headquarters building in California

Neuropsychiatric disorders

AbbVie Absorbs $3.5B Cost of Schizophrenia Flop

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.

January 13, 2025

2 min read

Tristan Manalac

Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration

ALS

HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.

January 10, 2025

5 min read

Heather McKenzie

JOBS